Evaluation of the Response Rate to Neoadjuvant Chemoradiotherapy in Patients with Rectal Adenocarcinoma: A Retrospective Long-term Study in Two Terciary Reference Centers

Abstract

Objectives To evaluate the complete response (CR) rate and surgeries performed in patients with rectal adenocarcinoma who underwent neoadjuvant therapy (NT) at Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo and at Hospital São Paulo, in Ribeirão Preto, from January 2007 to December 2017.

Methods We evaluated 166 medical records of patients with locally advanced rectal adenocarcinoma (T3, T4 or N + ) who underwent NT. The regimen consisted of performing conventional (2D) or conformational (three-dimensional-3D/ radiotherapy with modulated intensity – IMRT) at a dose of 45-50.4Gy associated with capecitabine 1650mg/m² or 5-fluorouracil (5FU) and leucovorin (LV). The following variables were analyzed: gender, age, pretreatment stage, radiotherapy, CR index, local and distant recurrence rates. Surgical treatment and complications were also evaluated.

Results The CR index was 28.3%. Patients treated with 3D/IMRT radiotherapy had a higher rate of CR (36.3% x 4.8%; p < 0.001), higher rates of clinical follow-up (21% x 0%; p < 0.001), lower surgery rates (79% x 100%; p < 0.001), higher rates of transanal resection (37.1% x 9.5%; p = 0.001), lower rates of abdominal rectosigmoidectomy (25.8% x 50%; p = 0.007) and lower rates of abdominoperineal resection of the rectum (16.1% x 40.5%; p = 0.002), when compared to patients treated with 2D radiotherapy.

Conclusion Modern radiotherapy techniques such as 3D conformal and IMRT, by offering greater adequacy and precision of treatment, could result in better local control and less toxicity in organs at risk, enabling organ preservation strategies and less invasive approaches in selected cases.

Keywords

rectal cancer - neoadjuvant therapy - radiotherapy

Publikationsverlauf

Eingereicht: 18. Juni 2023

Angenommen: 14. August 2023

Artikel online veröffentlicht:
21. September 2023

• References

• 1 INSTITUTO NACIONAL DE CÂNCER (Brasil). Câncer. Números de câncer. Rio de Janeiro: INCA, 2023 . Disponível em: https://www.gov.br/inca/pt-br/assuntos/cancer/numeros Acesso em: 31 de maio. 2022.
• 2 Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1 (8496) 1479-1482
• 3 Sauer R, Becker H, Hohenberger W. et al; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351 (17) 1731-1740
• 4 Sebag-Montefiore D, Stephens RJ, Steele R. et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009; 373 (9666) 811-820
• 5 Taylor FG, Quirke P, Heald RJ. et al; Magnetic Resonance Imaging in Rectal Cancer European Equivalence Study Study Group. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol 2014; 32 (01) 34-43
• 6 Benson AB, Venook AP, Al-Hawary MM. et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018; 16 (07) 874-901
• 7 Borger JH, van den Bogaard J, de Haas DF. et al. Evaluation of three different CT simulation and planning procedures for the preoperative irradiation of operable rectal cancer. Radiother Oncol 2008; 87 (03) 350-356
• 8 Corner C, Khimji F, Tsang Y, Harrison M, Glynne-Jones R, Hughes R. Comparison of conventional and three-dimensional conformal CT planning techniques for preoperative chemoradiotherapy for locally advanced rectal cancer. Br J Radiol 2011; 84 (998) 173-178
• 9 Luna-Pérez P, Rodríguez-Ramírez S, Hernández-Pacheco F, Gutiérrez De La Barrera M, Fernández R, Labastida S. Anal sphincter preservation in locally advanced low rectal adenocarcinoma after preoperative chemoradiation therapy and coloanal anastomosis. J Surg Oncol 2003; 82 (01) 3-9
• 10 Habr-Gama A. Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy. Colorectal Dis 2006; 8 (Suppl. 03) 21-24
• 11 Chen M, Chen LZ, Xu L, Zhang JS, Song X. Neoadjuvant chemoradiation for locally advanced rectal cancer: a systematic review of the literature with network meta-analysis. Cancer Manag Res 2019; 11: 741-758
• 12 Li Y, Wang J, Ma X. et al. A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. Int J Biol Sci 2016; 12 (08) 1022-1031
• 13 Park JH, Yoon SM, Yu CS, Kim JH, Kim TW, Kim JC. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. Cancer 2011; 117 (16) 3703-3712
• 14 Habr-Gama A, Perez RO, São Julião GP. et al. Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen. Radiat Oncol 2016; 11: 24
• 15 Appelt AL, Sebag-Montefiore D. Technological advances in radiotherapy of rectal cancer: opportunities and challenges. Curr Opin Oncol 2016; 28 (04) 353-358
• 16 Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2017; 2 (07) 501-513
• 17 Rocha JJ, Féres O. Transanal endoscopic operation: a new proposal. Acta Cir Bras 2008; 23 (Suppl. 01) 93-104 , discussion 104
• 18 Rocha JJ, Bernardes MV, Feitosa MR. et al. Transanal endoscopic operation for rectal cancer after neoadjuvant therapy. Acta Cir Bras 2016; 31 (Suppl. 01) 29-33